4,115 results match your criteria Borderline Ovarian Cancer


Predictive features of borderline ovarian tumor recurrence in patients with childbearing potential undergoing conservative treatment.

Mol Clin Oncol 2022 Jul 7;17(1):121. Epub 2022 Jun 7.

Department of Medicine and Surgery, University Hospital of Parma, I-43125 Parma, Italy.

Borderline ovarian tumors (BOT) represent 10-12% of ovarian cancer cases with a higher prevalence in young patients. Although reproductive outcomes are satisfactory after conservative treatment, several authors reported a higher relapse rate in patients undergoing fertility-sparing surgery compared with radical treatment. The aim of the present study was to identify predictive factors of BOT recurrence in patients with childbearing potential undergoing conservative treatment with unilateral salpingo-oophorectomy. Read More

View Article and Full-Text PDF

An evaluation of the microbiota of the upper reproductive tract of women with and without epithelial ovarian cancer.

Gynecol Oncol Rep 2022 Aug 10;42:101017. Epub 2022 Jun 10.

University of North Carolina at Chapel Hill, Department of Medicine, Center for Gastrointestinal Biology and Disease, United States.

Objective: The microbiome of the female upper reproductive tract (URT) has not been characterized. We hypothesize that distinct bacterial species may be identified in different areas of the URT in women with or without ovarian cancers.

Methods: Postmenopausal women scheduled for salpingooophorectomy were prospectively identified. Read More

View Article and Full-Text PDF

Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.

Curr Oncol 2022 Jun 1;29(6):4020-4033. Epub 2022 Jun 1.

Department of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan.

Few studies have reported hormonal agent use in the treatment of low-grade serous ovarian carcinomas (LGSOCs), which are chemoresistant. Considering the need for novel effective therapies, we investigated the hormone receptor expression and hormonal inhibition efficacy in LGSOCs. Using immunohistochemistry, we assessed the estrogen receptor (ER) expression status in 33 cases of histologically confirmed serous ovarian tumors, including 10, 11, and 12 cases of LGSOCs, serous borderline tumors (SBTs), and serous cystadenomas (SCAs), respectively. Read More

View Article and Full-Text PDF

Initiation and elongation factor co-expression correlates with recurrence and survival in epithelial ovarian cancer.

J Ovarian Res 2022 Jun 19;15(1):73. Epub 2022 Jun 19.

Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria.

High grade epithelial ovarian cancer (EOC) represents a diagnostic and therapeutic challenge due to its aggressive features and short recurrence free survival (RFS) after primary treatment. Novel targets to inform our understanding of the EOC carcinogenesis in the translational machinery can provide us with independent prognostic markers and provide drugable targets. We have identified candidate eukaryotic initiation factors (eIF) and eukaryotic elongation factors (eEF) in the translational machinery for differential expression in EOC through in-silico analysis. Read More

View Article and Full-Text PDF

Microcystic stromal tumor of the ovary: a recurrent case with somatic CTNNB1 missense mutation.

Virchows Arch 2022 Jun 14. Epub 2022 Jun 14.

Department of Gynecology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Microcystic stromal tumors (MCSTs) of the ovary are rare sex cord-stromal tumors that are considered benign neoplasms because almost all cases display unilateral, localized lesions and have benign outcomes, except for one recurrent case with familial adenomatous polyposis and another initial metastatic case with a CTNNB1 mutation. We report herein a sporadic case that relapsed as intra-abdominal spread 9 years and 1 month after primary left salpingo-oophorectomy for torsion of the ovarian tumor pedicle. The tumor relapsed as multiple disseminations at the subabdominal wall, Douglas pouch, and omentum. Read More

View Article and Full-Text PDF

Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?

Gynecol Oncol 2022 Jun 7. Epub 2022 Jun 7.

Hospital for Gynecologic Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Introduction: The value of serum human epididymis protein 4 (HE4) in guiding referral decisions in patients with an ovarian mass remains unclear, because the majority of studies investigating HE4 were performed in oncology hospitals. However, the decision to refer is made at general hospitals with a low ovarian cancer prevalence. We assessed accuracies of HE4 in differentiating benign or borderline from malignant tumors in patients presenting with an ovarian mass at general hospitals. Read More

View Article and Full-Text PDF

Fertility Preserving Surgery Outcomes for Ovarian Malignancy: Data from a Tertiary Cancer Centre in Central London.

J Clin Med 2022 Jun 3;11(11). Epub 2022 Jun 3.

Faculty of Life Sciences & Medicine at Guy's, The School of Life Course Sciences, King's College London, London WC2R 2LS, UK.

Fertility Sparing Surgery (FSS) appears to be a safe means of treating early-stage ovarian cancer based on relatively limited evidence. However, there is currently insufficient evidence to aid women in counselling about their potential fertility outcomes. The aim of this study was to assess the reproductive outcomes and prognosis of women who have undergone FSS for ovarian malignancy. Read More

View Article and Full-Text PDF

The Multimodal Ultrasound Features of Ovarian Serous Surface Papillary Borderline Tumor.

Womens Health Rep (New Rochelle) 2022 10;3(1):523-532. Epub 2022 May 10.

Department of Medical Ultrasound, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Aim: Ovarian serous surface papillary borderline tumor (OSSPBT) is very rare. Combined with clinical and pathological features, we aim to investigate the multimodal ultrasound features of OSSPBT.

Patients And Methods: There were only 18 patients diagnosed with OSSPBT among the 142 patients who were diagnosed with borderline serous ovarian tumor by pathology from June 2008 to December 2020 in our hospital. Read More

View Article and Full-Text PDF

Association Between Benign Ovarian Tumors and Ovarian Cancer Risk: A Meta-Analysis of Ten Epidemiological Studies.

Front Oncol 2022 12;12:895618. Epub 2022 May 12.

Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.

Background: Epidemiological evidence on the relationship between benign ovarian tumors and ovarian cancer risk has been controversial; therefore, this systematic review and meta-analysis evaluated this association.

Methods: The PubMed and Web of Knowledge databases were searched for eligible studies published up to April 30, 2020. The study-specific risk estimates were pooled using a random-effects model. Read More

View Article and Full-Text PDF

Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2019 and annual treatment report for 2014.

J Obstet Gynaecol Res 2022 May 27. Epub 2022 May 27.

Faculty of Medicine, Yamagata University, Yamagata, Japan.

Aim: To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2019 and the Annual Treatment Report for 2014, on the outcomes of patients who started treatment in 2014.

Methods: The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2019 were analyzed retrospectively. Read More

View Article and Full-Text PDF

The Comparison of Three Predictive Indexes to Discriminate Malignant Ovarian Tumors from Benign Ovarian Endometrioma: The Characteristics and Efficacy.

Diagnostics (Basel) 2022 May 12;12(5). Epub 2022 May 12.

Department of Obstetrics and Gynecology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Japan.

This study aimed to evaluate the prediction efficacy of malignant transformation of ovarian endometrioma (OE) using the Copenhagen Index (CPH-I), the risk of ovarian malignancy algorithm (ROMA), and the R2 predictive index. This retrospective study was conducted at the Department of Gynecology, Nara Medical University Hospital, from January 2008 to July 2021. A total of 171 patients were included in the study. Read More

View Article and Full-Text PDF

Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.

Curr Oncol 2022 05 18;29(5):3658-3667. Epub 2022 May 18.

Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo 6938501, Japan.

Ovarian seromucinous tumors (SMBTs) are relatively rare, and their carcinogenesis is largely unknown. In this study, the molecular features of SMBTs in Japan are assessed. DNA was extracted from microdissected paraffin-embedded sections from 23 SMBT cases. Read More

View Article and Full-Text PDF

Construction of ovarian metastasis-related immune signature predicting prognosis of gastric cancer patients.

Cancer Med 2022 May 27. Epub 2022 May 27.

Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

Background: Ovarian metastasis (OM) results in poor survival of gastric cancer (GC) patients. While immunotherapy has emerged as a promising approach for late-stage GC, validated immune-related prognostic signatures still remain in need. In this study, we constructed an ovarian metastasis- and immune-related prognostic signature (OMIRPS), characterized the molecular and immune features of OMIRPS-categorized subgroups and predicted their potential response to immunotherapy. Read More

View Article and Full-Text PDF

Ovarian tumor frozen section, a multidisciplinary affair.

Acta Oncol 2022 Jul 25;61(7):785-792. Epub 2022 May 25.

Division of Oncology, Department of Clinical Science, Skåne University Hospital, Lund University, Lund, Sweden.

Background: Ovarian Cancer (OC) constitute the eighth most common cancers among women worldwide. Surgery remains the cornerstone in the management of OC. Intraoperative frozen section (FS) diagnosis is widely used to decide the surgery course. Read More

View Article and Full-Text PDF

Xanthogranulomatous salpingo-oophoritis presenting as an ovarian tumour.

BMJ Case Rep 2022 May 19;15(5). Epub 2022 May 19.

Gynecology, Centro Hospitalar de Vila Nova de Gaia Espinho EPE, Vila Nova de Gaia, Portugal.

Xanthogranulomatous salpingo-oophoritis (XGSO) is an exceptionally rare entity. Its clinical manifestations and imaging modalities can mimic benign and malignant adnexal diseases, making it difficult to diagnose. Here we report a case of XGSO in a young woman who was operated with suspicion of a borderline ovarian tumour. Read More

View Article and Full-Text PDF

The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance.

Virchows Arch 2022 May 13. Epub 2022 May 13.

Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic.

We assessed the value of cytokeratin 17 (CK17) expression for the differential diagnosis between primary ovarian mucinous tumors and metastases from the gastrointestinal tract (GIT) and the significance of CK17 expression in a broad spectrum of primary ovarian tumors with respect to their prognosis. The sample set consisted of 554 primary ovarian tumors and 255 GIT tumors. In the primary ovarian tumors, a higher CK17 expression (in > 10% of tumors cells) was present only in 0-11. Read More

View Article and Full-Text PDF

Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis.

Front Endocrinol (Lausanne) 2022 21;13:871210. Epub 2022 Apr 21.

Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Medical Oncology, ASST Spedali Civili, Brescia, Italy.

Background: Ovarian strumal carcinoid is a rare tumor in which thyroid (struma) and carcinoid components coexist. The disease is generally considered to be a borderline malignancy, however, cases with metastatic disease have been described. No data in the literature are available to guide diagnosis and therapy. Read More

View Article and Full-Text PDF

Male-origin microchimerism and endometrial cancer: A prospective case-cohort study.

Cancer Epidemiol 2022 May 5;79:102169. Epub 2022 May 5.

Section of Epidemiology, Department of Public Health, University of Copenhagen, Denmark.

Background: Many women carry male cells of presumed fetal origin-so-called male-origin microchimerism (MOM)-in their circulation and tissues. Studies have found reduced risks of hormone dependent cancers, including breast and ovarian cancer, among MOM-positive women. The aim of this study was to investigate the association between MOM and endometrial cancer. Read More

View Article and Full-Text PDF

BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma.

Int J Gynecol Pathol 2022 May 20. Epub 2022 May 20.

James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Peritoneal mesothelioma (PM) and serous neoplasms can be difficult to differentiate, particularly in small biopsies. BRCA1-associated protein 1 (BAP1) is expressed in benign tissues, but over 50% of PMs demonstrate complete loss of nuclear expression. Claudin-4, a tight junction protein, is expressed in most epithelial tumors but not in mesotheliomas. Read More

View Article and Full-Text PDF

A rare case of an androgen-secreting mucinous borderline ovarian tumour in a perimenopausal woman.

Br J Hosp Med (Lond) 2022 04 29;83(4):1-5. Epub 2022 Apr 29.

Department of Diabetes and Endocrinology, Mater Dei Hospital, Msida, Malta.

View Article and Full-Text PDF

Usefulness of dynamic contrast-enhanced magnetic resonance imaging in characterizing ovarian tumors classified as indeterminate at ultrasonography.

Radiologia (Engl Ed) 2022 Mar-Apr;64(2):110-118

Servicio de Radiodiagnóstico, Complexo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain.

Objectives: To determine whether there is a significant relationship between the shape of the time-intensity curve on dynamic gadolinium-enhanced magnetic resonance imaging (MRI) of ovarian tumours classified as indeterminate at ultrasonography and the type of lesion (benign, borderline, or malignant) to enable an accurate presurgical diagnosis.

Material And Methods: We used dynamic contrast-enhanced MRI to study 68 ovarian tumours that were classified as indeterminate at ultrasonography. We included only cases for which a definitive diagnosis (histologic diagnosis or ≥1 year stability on imaging tests) was available. Read More

View Article and Full-Text PDF

Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer.

NPJ Genom Med 2022 Apr 28;7(1):30. Epub 2022 Apr 28.

Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.

Fragmentation patterns of plasma cell-free DNA (cfDNA) are known to reflect nucleosome positions of cell types contributing to cfDNA. Based on cfDNA fragmentation patterns, the deviation in nucleosome footprints was quantified between diagnosed ovarian cancer patients and healthy individuals. Multinomial modeling was subsequently applied to capture these deviations in a per sample nucleosome footprint score. Read More

View Article and Full-Text PDF

Oncological and reproductive outcomes after fertility-sparing surgery in patients with seromucinous borderline ovarian tumor: Results of a large retrospective study.

Gynecol Oncol 2022 Jun 22;165(3):446-452. Epub 2022 Apr 22.

Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, National Clinical Research Center for Obstetric and Gynecologic Diseases, Beijing 100730, People's Republic of China. Electronic address:

Objective: To evaluate the oncological and reproductive outcomes in patients with seromucinous borderline ovarian tumors (SMBOT) treated with fertility-sparing surgery (FSS).

Methods: We retrospectively reviewed the medical records of patients with SMBOT who underwent surgery between 2000 and 2019. A centralized histological review was performed and recurrence rates were compared between different surgical procedures. Read More

View Article and Full-Text PDF

Significance of Endocan Expression in Various Types of Epithelial Ovarian Tumors.

Iran J Pathol 2022 8;17(2):202-209. Epub 2022 Mar 8.

Department of Pathology, Faculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

Background & Objective: Ovarian cancer is associated with the highest mortality rate among gynecologic malignancies. Despite new therapeutic strategies, ovarian cancer still has a high risk of metastasis and mortality. Endocan is a newly identified endothelial cell activation marker, which is responsible for angiogenesis, tumor invasion, and aggressive behavior of tumors. Read More

View Article and Full-Text PDF

Revisiting the necessity for routine appendectomies in mucinous neoplasms of the ovary: An evaluation of 460 mucinous ovarian tumors.

Ann Diagn Pathol 2022 Aug 9;59:151950. Epub 2022 Apr 9.

Department of Pathology, University of California San Diego, La Jolla, CA, United States of America. Electronic address:

Appendectomies are not uncommonly performed following an intraoperative diagnosis of a mucinous ovarian neoplasm, although the evidentiary basis for the practice is relatively limited. The current study is a contemporary re-examination of the issue, based on an analysis of a large single institutional cohort. We assessed whether there are any composite of factors that may be associated with the finding of significant disease in the appendix in this setting following intraoperative consultation (IOC) diagnosis of a mucinous neoplasm on an ovary-based mass. Read More

View Article and Full-Text PDF

Identification of clinical and molecular features of recurrent serous borderline ovarian tumour.

EClinicalMedicine 2022 Apr 8;46:101377. Epub 2022 Apr 8.

State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Institute of Metabolism and Integrative Biology, Obstetrics and Gynecology Hospital of Fudan University, Fudan University, Shanghai 200438, China.

Background: Serous borderline ovarian tumour (SBOT) is the most common type of BOT. Fertility sparing surgery (FSS) is an option for patients with SBOT, though it may increase the risk of recurrence. The clinical and molecular features of its recurrence are important and need to be investigated in detail. Read More

View Article and Full-Text PDF

Precursors in the ovarian stroma: another pathway to explain the origin of ovarian serous neoplasms.

Hum Pathol 2022 Apr 12. Epub 2022 Apr 12.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Ovarian serous neoplasms are thought to arise from the fallopian tube or from the ovarian surface epithelium. The possibility of a third pathway-involving the mesenchymal-epithelial transition and mimicking the formation of the Müllerian duct-arose from observations gathered from our routine cases. The purpose of this study is to determine the association of precursors in the ovarian stroma with different types of ovarian serous neoplasms. Read More

View Article and Full-Text PDF

Endocrine cell micronests in an ovarian mucinous borderline tumor: a potential diagnostic pitfall for microinvasion.

Diagn Pathol 2022 Apr 14;17(1):37. Epub 2022 Apr 14.

Department of Pathology, Indiana University, 350 W 11th Street, IN, 46202, Indianapolis, USA.

The occurrence of endocrine cell micronests in ovarian tumors is rarely reported. To our knowledge, there are only three prior cases reported to date: one occurring in an ovarian mucinous cystadenoma, one in an ovarian mucinous cystadenofibroma, and another in an ovarian mucinous carcinoma with a predominant borderline component. This is a 27-year-old woman that presented with a one-month history of abdominal pain and fullness. Read More

View Article and Full-Text PDF

Peripheral lymphocyte populations in ovarian cancer patients and correlations with clinicopathological features.

J Ovarian Res 2022 Apr 11;15(1):43. Epub 2022 Apr 11.

Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Background: To investigate the alterations of peripheral lymphocyte subpopulations in ovarian cancer patients compared to benign or borderline counterparts. The possible clinicopathological implications were also evaluated.

Methods: We enrolled 112 treatment-naive ovarian cancer patients, 14 borderline tumor patients and 44 benign tumor patients between 09/2016 and 01/2019. Read More

View Article and Full-Text PDF